Temafloxacin

WikiDoc Resources for Temafloxacin
Articles
Most recent articles on Temafloxacin Most cited articles on Temafloxacin Review articles on Temafloxacin Articles on Temafloxacin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Temafloxacin Images of Temafloxacin Photos of Temafloxacin Podcasts & MP3s on Temafloxacin Videos on Temafloxacin
Evidence Based Medicine
Cochrane Collaboration on Temafloxacin Bandolier on Temafloxacin TRIP on Temafloxacin
Clinical Trials
Ongoing Trials on Temafloxacin at Clinical Trials.gov Trial results on Temafloxacin Clinical Trials on Temafloxacin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Temafloxacin NICE Guidance on Temafloxacin NHS PRODIGY Guidance FDA on Temafloxacin CDC on Temafloxacin
Books
Books on Temafloxacin
News
Temafloxacin in the news Be alerted to news on Temafloxacin News trends on Temafloxacin
Commentary
Blogs on Temafloxacin
Definitions
Definitions of Temafloxacin
Patient Resources / Community
Patient resources on Temafloxacin Discussion groups on Temafloxacin Patient Handouts on Temafloxacin Directions to Hospitals Treating Temafloxacin Risk calculators and risk factors for Temafloxacin
Healthcare Provider Resources
Symptoms of Temafloxacin Causes & Risk Factors for Temafloxacin Diagnostic studies for Temafloxacin Treatment of Temafloxacin
Continuing Medical Education (CME)
CME Programs on Temafloxacin
International
Temafloxacin en Espanol Temafloxacin en Francais
Business
Temafloxacin in the Marketplace Patents on Temafloxacin
Experimental / Informatics
List of terms related to Temafloxacin

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Temafloxacin (marketed by Abbott Laboratories as Omniflox), is a fluoroquinolone antibiotic drug which was withdrawn from sale in the U.S. shortly after its approval in 1992 because of serious adverse reactions resulting in three deaths.

Omniflox was approved to treat lower respiratory tract infections, genital and urinary infections like prostatitis, and skin infections in the U.S. by the Food and Drug Administration in January 1992. Severe adverse reactions, including allergic reactions and hemolytic anemia, developed in about fifty patients during the first four months of its use, leading to three patient deaths. Abbott withdrew the drug from sale in June 1992.

External links

• FDA press release June 5, 1992.